Embecta Corp. has announced a definitive agreement to acquire Owen Mumford Holdings Limited for up to $199.4 million (£150 million). This strategic move aims to significantly expand Embecta’s drug delivery capabilities and accelerate its transformation into a broad-based medical supplies company.
Embecta, formerly the BD Diabetes business, is set to acquire Owen Mumford, a UK-based innovator and manufacturer of medical devices and drug delivery technologies. The acquisition is valued at up to £150 million, comprising an initial cash payment of £100 million and an additional £50 million contingent on the net sales of Owen Mumford’s Aidaptus® next-generation auto-injector platform over the three years following the closing. This transaction, unanimously approved by Embecta’s Board of Directors, is anticipated to conclude in Embecta’s fiscal third quarter of 2026, pending regulatory approvals and other closing conditions.
Owen Mumford, founded in 1952, has established a strong reputation as a partner to pharmaceutical, biotech, and healthcare organizations. Its product portfolio includes a growing pharmaceutical services segment built on its auto-injector success, anchored by the Aidaptus® platform. The company also offers medical devices for point-of-care testing, self-injection, and pelvic health. These offerings are highly complementary to Embecta’s existing diabetes care franchise and commercial infrastructure, providing a differentiated drug delivery platform with a robust intellectual property portfolio. In fiscal year 2025, Owen Mumford generated approximately 80% of its revenue in the UK and the U.S., presenting a significant opportunity for Embecta to leverage its global commercial presence in over 100 countries.
Embecta anticipates the acquisition will contribute to revenue growth starting in fiscal year 2027. While the transaction is expected to be immaterial to Embecta’s fiscal year 2027 adjusted operating income and dilutive to adjusted net income in the same year, it is projected to become accretive thereafter. The company expects to achieve a high-single-digit return on invested capital by the fourth year post-acquisition. Analysts from BTIG have maintained a “Buy” rating for Embecta, viewing the transaction favorably for its move into adjacent markets, enhancement of B2B efforts, and addition of the Aidaptus® platform at a reasonable valuation. The market has reacted positively, with Embecta’s stock showing an increase following the announcement.